Erythromycin
FDA Approved
Description
Erythromycin is a macrolide antibiotic with prokinetic properties that stimulate gastrointestinal motility through motilin receptor agonism. It is used off-label in managing intestinal dysmotility disorders including intestinal dysganglionosis and Berdon syndrome (megacystis-microcolon-intestinal hypoperistalsis syndrome). The prokinetic effect helps improve intestinal transit in patients with severe dysmotility.
Indications & Therapeutic Use
Bacterial infections, gastroparesis, intestinal dysmotility disorders (off-label)
Global Availability (8 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Erythromycin
| Generic Name | Erythromycin |
| Brands | 1 brand available |
| Active Ingredient | Erythromycin |
| Drug Class | Bacterial infections |
| Manufacturer | Various |
| Dosage Forms | Oral tablets 250mg, 500mg; IV infusion; Oral suspension 200mg/5mL |
| Medical Code | J01FA01 |
| Orphan Status | No |
| Cold Chain | Not Required |
| Lead Time | 2 days |
| Reg. Status | FDA Approved |
| Countries | 8 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations9 Validated Nodes